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Abstract
Background: Clostridium difficile infection (CDI) remains one of the major hospital acquired infections in the nation,
often attributable to increased antibiotic use. Little research, however, exists on the prevalence and impact of CDI
on patient and hospital outcomes among populations requiring such treatment. As such, the goal of this study was
to examine the prevalence, risk factors, and impact of CDI among pneumonia and urinary tract infection (UTI)
hospitalizations.
Methods: The Nationwide Inpatient Sample (2009–2011), reflecting a 20% stratified sample of community hospitals in
the United States, was used. A total of 593,038 pneumonia and 255,770 UTI discharges were included. Survey-weighted
multivariable regression analyses were conducted to assess the predictors and impact of CDI among pneumonia and
UTI discharges.
Results: A significantly higher prevalence of CDI was present among men with UTI (13.3 per 1,000) as compared
to women (11.3 per 1,000). CDI was associated with higher in-hospital mortality among discharges for pneumonia
(adjusted odds ratio [aOR] for men = 3.2, women aOR = 2.8) and UTI (aOR for men = 4.1, women aOR = 3.4). Length of
stay among pneumonia and UTI discharges were also double upon presence of CDI. In addition, CDI increased
the total charges by at least 75% and 55% among pneumonia and UTI discharges, respectively. Patient and hospital
characteristics associated with CDI included being 65 years or older, Charlson Deyo index for comorbidity of 2 or more,
Medicare as the primary payer, and discharge from urban hospitals, among both pneumonia and UTI discharges.
Conclusion: CDI occurs frequently in hospitalizations among those discharged from hospital for pneumonia and UTI,
and is associated with increased in-hospital mortality and health resource utilization. Interventions to mitigate the
burden of CDI in these high-risk populations are urgently needed.
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Background
Clostridium difficile infection (CDI) is a leading cause of
hospital-acquired infection (HAI) [1-3]. In many areas of
the United States, CDI has surpassed methicillin-resistant
Staphylococcus aureus as the most common type of HAI
[1] with approximately 333,000 initial and 145,000 recur-
rent hospital-onset cases in the nation [4]. Certain patient
populations have a disproportionately higher risk for CDI
due to either host factors, frequent antibiotic use or both.
These include older adults, patients using proton pump
inhibitors [5-7] or antibiotics [8,9], those with inflamma-
tory bowel disease [10-12], end-stage renal failure, or re-
cipients of solid organ transplants [13,14].
In a study addressing the burden of CDI among patients
with inflammatory bowel disease, Ananthakrishnan et al.
[12] demonstrated four times higher mortality and three
days longer hospital stay with presence of CDI. Similarly,
among solid organ transplant patients, presence of CDI
significantly increased the in-hospital mortality, length of
stay, and charges, in addition to organ complications [14].
Despite such recognized burden of CDI, limited research
exists on the prevalence and impact of infection among
most common conditions that require antimicrobial treat-
ment, with no study to date evaluating such impact among
pneumonia or urinary tract infection (UTI) patients. Some
recent empirical evidence has noted the co-occurrence
of pneumonia and UTI with CDI in the United States
[15] putatively due to the use of antimicrobial treatment;
though none have evaluated the impact of such co-
occurrences on patient and hospital outcomes. Misdiag-
nosis of pneumonia and inappropriate use of antimicrobial
therapy was associated with a CDI outbreak [16]. Given
the burden of CDI nationally and increasing prevalence at-
tributed at least in part to antibiotic use, understanding
the impact of CDI among patients with pneumonia or
UTI would be valuable to devise potential preventive
strategies. We undertook analyses of an existing large
dataset from a nationally representative survey to assess
[1] the prevalence and factors associated with CDI
among pneumonia and UTI and [2] the impact of CDI
on in-hospital mortality and health resource utilization
(length of stay [LOS] and total charges).
Methods
Data source
Data was extracted from the Nationwide Inpatient Sample
(NIS), 2009–2011. NIS, considered the largest publically
available all-payer inpatient database in the United States,
includes data from all states that participate in the Health-
care Cost and Utilization Project (HCUP), sponsored by
the Agency for Healthcare Research and Quality (AHRQ).
An annual approximate sample of 8 million hospitalizations
from 1,000 hospitals, reflecting a 20% stratified sample of
community hospitals in the nation are included in NIS. NIS
excludes short-term rehabilitation hospitals (starting 1998
data), long-term non-acute care hospitals, psychiatric
hospitals, and alcoholism/chemical dependency treatment
facilities. All hospitals in NIS are stratified based on five
hospital characteristics: ownership/control, bed size, teach-
ing status, urban/rural location, and geographic location.
Starting 1988, NIS data is available yearly and further
details of the dataset are available elsewhere [17].
Data collection and study definitions
Our study sample included hospital primary discharges
with pneumonia or UTI in adults over the age of 17 years.
The International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) was used to identify
UTI (599.0) and CDI (008.45). Pneumonia was assessed
using Clinical Classification Software (CCS) code of 112,
representing cases not caused by tuberculosis or sexually
transmitted disease (as defined by NIS). Similar coding
strategies have been utilized in previous literature for CDI
[11,13,14], pneumonia [18,19], and UTI [20,21]. NIS pro-
vides a primary discharge code in addition to additional
codes of secondary diagnoses. In this study, patients with
secondary discharge code for CDI were identified as CDI
patients.
We further included both patient and hospital character-
istics, to both control for and evaluate if such characteristics
negatively impact CDI patients. For example, previous
research has demonstrated both patient socioeconomic
factors and hospital characteristics, to be positively associ-
ated with length of stay and mortality in other patient
populations [11,13,14,22,23], and thus such variables were
further accounted for in our study.
Patient characteristics included were: age (18–34 years,
35–49 years, 50–64 years, 65 years or more), gender (men,
women), race/ethnicity (White, Black, Hispanic, Asian or
Pacific Islander, Native American, other), primary payer
type (Private including HMO, Medicare, Medicaid, Self-
pay, no charge, other), neighborhood income defined as
median household income quartiles by patient ZIP code
($1-$38999, $39000-$47999, $48000-$62999, $63000 or
more) and Charlson-Deyo Index (0, 1, 2 or more). The
Deyo modification of the Charlson comorbidity index was
used, which creates a score representing co-morbidities
for each discharge utilizing the ICD-9-CM coding algo-
rithms. The 17-item index is a validated measure of co-
morbidity for administrative data [24-26].
Hospital characteristics included in the study were: bed
size tertile categories (small, medium, large), ownership/
control (private investor-own, private non-profit, gov-
ernment nonfederal), setting/teaching status (rural, urban
non-teaching, urban teaching), and geographic location
(Northeast, Midwest, South, West). In-hospital mortality
was defined as those who died during hospitalization ver-
sus those who did not. LOS and total charges were used
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from NIS-provided variables, which were edited by AHRQ
to ensure uniformity between states. Total charges were
adjusted quarterly for inflation using the Gross Domestic
Product (GDP) deflator available through the United
States Department of Commerce, Bureau of Economic
Analysis with 2009 USD as the reference year [27].
Statistical analyses
SAS 9.4 (SAS Institute, Inc., Cary, NC) was used for all
statistical analyses except for negative binomial regres-
sion, for which we used the STATA 12 package (Stata
Corp LP, College Station, TX). Given that existing data
suggests potential gender differences in CDI [28-30] all
statistical analyses were stratified by gender. Due to the
large number of variables and in turn multiple testing, a
family-wise correction using the Bonferroni adjustment
was conducted to reduce type I error rate. As a result,
P < 0.0017 was set as the level of significance.
To assess CDI prevalence (for each patient population),
in addition to patient and hospital characteristic differences
between each gender among pneumonia and UTI cases,
chi-square tests using design-based F values were used. The
prevalence of secondary CDI was noted as cases per 1,000
discharges for pneumonia and UTI groups, by gender.
Next, independent survey-weighted multivariable logistic
regression analyses were performed to identify patient and
hospital characteristics associated with prevalence of
secondary CDI in both primary pneumonia and UTI
discharges.
In order to identify the impact of secondary CDI on
in-hospital mortality among patients hospitalized for pri-
mary pneumonia or UTI, chi-square tests were conducted
followed by survey-weighted logistic regression analyses.
To assess the impact of secondary CDI on resource
utilization, Wilcoxon rank sum test was used, followed
by survey-weighted negative binomial regression and
survey-weighted linear regression for LOS and total
charges, respectively. For all adjusted models in each
regression analyses, control variables of survey year,
patient, and hospital characteristics were included. Since
the distribution of total charges was non-normal and
skewed to the right, this variable was natural log trans-
formed for linear regression analyses. In addition, given
that descriptive analyses demonstrated a significantly
higher percent of our population as 65 or older and the
elderly are more likely to have negative health impacts
[31-33], a sensitivity analysis was performed in the afore-
mentioned adjusted models among patients aged 65
and older. Model building for all analyses included as-
sessment of assumptions and relevant interaction terms
(sociodemographic characteristics with hospital character-
istics), with significance established at P < .05. The study
was submitted to the University of Wisconsin-Madison
Institutional Review Board and was considered exempt
from review.
Results
A total of 593,038 pneumonia and 255,770 UTI discharges
were included in this study. Of them, 6,427 cases of
secondary CDI among pneumonia patients and 3,037
secondary CDI cases among UTI patients were noted,
representing 10.8 secondary CDI cases per 1,000 pneumo-
nia discharges and 11.1 secondary CDI cases per 1,000
UTI discharges.
Gender specific analyses found a total of 2,996 and 1,000
cases of secondary CDI among men with pneumonia and
UTI, respectively. Among women, 3,431 cases of secondary
CDI were noted among those hospitalized for pneumonia
and an additional 2,037 cases among those with primary
UTI. Table 1 summarizes the prevalence of secondary CDI,
patient, and hospital characteristics among primary pneu-
monia and UTI discharges, by gender. While rates of CDI
among those with pneumonia did not differ between each
gender, significant difference was noted for UTI patients,
with men reporting 13.3 cases of secondary CDI per 1,000
compared to 11.3 cases per 1,000 for women (P < 0.001).
As further noted in Table 1, several patient and hospital
characteristics were significantly different among men and
women and as a result all such variables were included in
final model building for regression analyses.
Table 2 displays the factors significantly associated
with secondary CDI among primary pneumonia and
UTI discharges. Among hospitalizations for pneumonia,
increased odds of CDI were associated with being 65 years
or older (adjusted odds ratio [aOR] for men = 1.7; aOR for
women = 1.9), having Medicare as the primary payer (aOR
men and women = 1.3), and increasing Charlson Deyo
index (aOR men = 1.5; aOR women = 1.8). CDI was also
significantly associated with high income (aOR = 1.3)
and Medicaid (aOR = 1.4) among men hospitalized for
pneumonia. Furthermore, for both men and women,
hospitalization at urban non-teaching facilities was as-
sociated with approximately 60% increased odds of CDI
while nearly double the odds were noted if hospitalized
at urban teaching centers. On the other hand, lower
odds were noted among men admitted at government
nonfederal hospitals, as compared to investor-owned
facilities (aOR = 0.7).
Similar trends were noted for UTI discharges. Being
65 years or older (aOR = 2.4 for men only), highest in-
come category (aOR = 1.5 for men only), increasing co-
morbidities (aOR men = 1.3; aOR women = 1.7), urban
teaching status (aOR men = 1.9; aOR women = 1.7), and
urban non-teaching status (aOR = 1.4 for women only)
were also significantly associated with increased likeli-
hood of secondary CDI.
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Table 1 Prevalence of CDI, patient and hospital characteristics among primary pneumonia and UTI discharges, NIS 2009-2011
Pneumonia UTI
Men Women P value Men Women P value
n 279,072 313,966 75,600 180,170
N 462,171 519,849 125,338 298,156
Prevalence of secondary CDI, cases per 1,000 10.7 10.9 0.52 13.3 11.3 <0.001
Patient Characteristics
Age, %
18-34 years old 5.7 5.0 3.2 3.8
35-49 years old 10.6 10.4 <0.001 6.3 5.4 <0.001
50-64 years old 22.4 21.2 15.7 11.8
65 years old or more 61.3 63.3 74.9 78.9
Race/ethnicity, %
White 75.4 75.5 71.8 74.9
Black 11.5 12.0 14.9 12.1
Hispanic 7.8 7.5 <0.001 8.7 8.3 <0.001
Asian or Pacific Islander 2.0 1.8 1.5 1. 7
Native American 0.8 0.8 0.6 0.6
Other 2.6 2.4 2.6 2.3
Charlson-Deyo Index, %
0 20.8 21.3 28.0 33.0
1 26.7 31.8 <0.001 23.5 27.3 <0.001
2 or more 52.5 46.8 48.5 39.8
Neighborhood income, %
$1 - $38,999 32.0 32.9 30.1 30.4
$39,000 - $47,999 27. 2 27.0 <0.001 24.9 25.4 0.009
$48,000 - 62,999 23.0 22.8 24.0 23.9
$63,000 or more 17.7 17.3 21.0 20.3
Payer type, %
Private including HMO 19.1 17.9 12.2 10.4
Medicare 64.5 66.7 77.2 79.6
Medicaid 8.4 9.8 <0.001 6.8 6.7 <0.001
Self-pay 4.8 3.6 1.8 2.1
No Charge 0.5 0.4 0.2 0.2
Other 2.6 1.7 1.7 1.0
Hospital Characteristics
Bed size, %
Small 19.0 19.7 16.4 16.8
Medium 24.9 25.2 <0.001 24.8 25.3 0.06
Large 56.1 55.2 58.8 57.9
Hospital control, %
Private, investor-own 14.4 14.7 15.3 16.2
Private, non-profit 71.0 71.3 0.001 70.8 71.3 <0.001
Government, nonfederal 14.6 14.0 13.9 12. 6
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Results of chi-square analyses demonstrated that in-
hospital mortality was higher among pneumonia patients
diagnosed with CDI, as compared to those without, for
both men (13% vs. 4%, P < 0.0001) and women (11% vs.
4%, P < 0.0001). A similar effect of CDI among UTI dis-
charges was noted in regards to in-hospital mortality
among men (4% vs. 1%, P < 0.0001) and women (3% vs.
1%, P < 0.0001).
Table 3 shows the results of regression analyses (un-
adjusted and adjusted) to evaluate the impact of CDI on
in-hospital mortality and resource utilization among
pneumonia and UTI cases. After adjusting for control
variables, in-hospital mortality was approximately three
times higher for pneumonia cases with CDI as compared
to those without CDI. Having CDI among men hospital-
ized for UTI also increased the likelihood of in-hospital
mortality by four times. Similarly, among women with
UTI, CDI was associated with three times the odds of
dying in the hospital.
Wilcoxon rank sum tests demonstrated that median
LOS was significantly longer in pneumonia cases with
CDI as compared to those without CDI for both men
and women (9 days vs. 4 days, P < 0.0001). Similar trends
were noted for UTI with or without CDI (7 days vs.
3 days, P < 0.0001). Adjusted results of negative binomial
regression analyses showed that having CDI for pneu-
monia and UTI discharges was associated with approxi-
mately 200% increased LOS (Table 3).
Among men with pneumonia, higher median total
charges ($104131 vs. $41157, P < 0.0001) were noted
upon presence of CDI, with a similar trend reported
among women ($96446 vs. $40700, P < 0.0001). Median
total charges were also substantially higher upon UTI
cases with CDI for both men ($63842 vs. $34182, P <
0.0001) and women ($33063 vs. $61577, P < 0.0001) as
well. Results from multiple linear regression analyses
showed that secondary CDI was significantly associated
with increased percent change in total charges for both
pneumonia and UTI cases. For example, presence of sec-
ondary CDI increased total charges by 80% and 75%
among men and women with pneumonia, respectively.
Similarly, CDI was associated with 59% and 57% increase
in total charges among men and women with UTI, re-
spectively (Table 3). After conducting a sensitivity analysis
among ages 65 and older, a similar trend persisted for
in-hospital mortality, LOS, and total charges (Table 4).
Cumulatively, presence of secondary CDI among pneu-
monia or UTI discharges was substantially associated
with increased in-hospital mortality and health resource
utilization.
Discussion
Our study found that CDI is highly prevalent in patients
with pneumonia or UTI and is associated with signifi-
cantly increased in-hospital mortality, LOS, and total
charges. To our knowledge, this study is the first of its
kind to examine secondary CDI using a nationally repre-
sentative dataset in patients with pneumonia or UTI, both
frequent conditions that often require hospitalization and
antimicrobial therapy.
In our analyses, the prevalence of CDI is considerably
higher compared to that reported among general hospi-
talized patients, but lower than prevalence noted among
those with conditions that may uniquely predispose pa-
tients to CDI, such as ulcerative colitis [11,12]. We also
found a gender difference in CDI prevalence, with higher
rates noted among men with UTI as compared to women.
Such gender differences may be attributable to differences
in antibiotic prescribing practices as duration of treatment
for men with UTI is generally longer [34-37]. Future
Table 1 Prevalence of CDI, patient and hospital characteristics among primary pneumonia and UTI discharges, NIS 2009-2011
(Continued)
Setting, %
Rural 22.1 22.7 16.6 17.8
Urban non-teaching 44.0 44.8 <0.001 44.9 46.3 <0.001
Urban teaching 33.9 32.5 38.4 35.8
Region, %
Northeast 18.8 18.0 22.1 19.9
Midwest 25.3 25.6 <0.001 22.5 22.7 <0.001
South 38.9 40.6 40.4 42.7
West 16.9 15.9 15.1 14.7
Year, %
2009 34.1 34.1 32.5 32.0
2010 32.3 32.1 0.24 34.0 33.3 0.005
2011 33.5 33.8 33.5 34.7
CDI = Clostridium difficile infection, UTI = Urinary tract infection, n = total sample size, N = weighted average annual population estimate, CI = confidence interval
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Table 2 Determinants of CDI among pneumonia and UTI discharges, NIS 2009-2011
Pneumonia UTI
Men Women Men Women
Patient characteristics
Age
18-34 years old (ref.)
35-49 years old 0.98 (0.74, 1.31) 0.84 (0.61, 1.14) 0.82 (0.49, 1.38) 1.49 (0.96, 2.33)
50-64 years old 1.27 (0.97, 1.65) 1.34 (1.00, 1.78) 0.84 (0.53, 1.33) 1.92 (1.19, 3.11)
65 years old or more 1.70 (1.28, 2.25)* 1.85 (1.40, 2.45)* 0.94 (0.61, 1.44) 2.41 (1.47, 3.95)*
Race/ethnicity
White (ref.)
Black 0.92 (0.79, 1.07) 1.02 (0.89, 1.16) 1.08 (0.87, 1.34) 1.01 (0.86, 1.18)
Hispanic 1.02 (0.86, 1.21) 0.84 (0.71, 1.00) 0.85 (0.63, 1.15) 0.88 (0.73, 1.08)
Asian/Pacific Islander 1.26 (0.97, 1.62) 0.91 (0.69, 1.20) 0.96 (0.55, 1.67) 0.88 (0.60, 1.28)
Native American 1.50 (0.86, 2.62) 0.84 (0.50, 1.43) 0.57 (0.14, 2.31) 0.66 (0.28, 1.56)
Other 1.14 (0.87, 1.50) 1.14 (0.87, 1.47) 1.24 (0.82, 1.87) 0.84 (0.58, 1.21)
Charlson-Deyo Index
0 (ref.)
1 0.98 (0.86, 1.13) 1.16 (1.02, 1.32) 0.88 (0.72, 1.09) 1.18 (1.03, 1.36)
2 or more 1.54 (1.36, 1.75)* 1.81 (1.59, 2.05)* 1.31 (1.10, 1.55)* 1.72 (1.53, 1.94)*
Neighborhood income
$1 - $38,999 (ref.)
$39,000 - $47,999 1.08 (0.96, 1.23) 1.07 (0.95, 1.21) 1.09 (0.86, 1.37) 0.89 (0.77, 1.03)
$48,000 - 62,999 1.12 (0.98, 1.27) 1.10 (0.97, 1.25) 1.29 (1.04, 1.59) 1.17 (1.01, 1.36)
$63,000 or more 1.30 (1.13, 1.49)* 1.23 (1.07, 1.43) 1.52 (1.21, 1.90)* 1.17 (0.98, 1.39)
Payer type
Private including HMO (ref.)
Medicare 1.32 (1.15, 1.51)* 1.26 (1.09, 1.45)* 1.21 (0.95, 1.55) 0.90 (0.74, 1.10)
Medicaid 1.38 (1.14, 1.68)* 1.19 (0.98, 1.45) 1.04 (0.72, 1.50) 1.00 (0.78, 1.28)
Self-pay 0.69 (0.49, 0.96) 0.87 (0.61, 1.23) 0.25 (0.08, 0.78) 0.53 (0.30, 0.94)
No Charge 1.28 (0.66, 2.50) 0.54 (0.17, 1.72) 0.74 (0.13, 4.42) 0.38 (0.05, 2.75)




Medium 0.92 (0.78, 1.09) 1.03 (0.88, 1.20) 1.02 (0.80, 1.30) 0.88 (0.74, 1.04)
Large 1.09 (0.94, 1.27) 1.17 (1.01, 1.35) 1.19 (0.96, 1.48) 0.97 (0.83, 1.14)
Hospital control
Private investor-own (ref.)
Private non-profit 0.79 (0.68, 0.92) 0.86 (0.74, 1.00) 1.01 (0.79, 1.28) 1.15 (0.96, 1.37)
Government nonfederal 0.68 (0.55, 0.84)* 0.76 (0.63, 0.93) 0.88 (0.63, 1.23) 1.06 (0.84, 1.35)
Setting
Rural (ref.)
Urban non-teaching 1.63 (1.36, 1.96)* 1.66 (1.40, 1.98)* 1.63 (1.20, 2.20) 1.42 (1.16, 1.73)*
Urban teaching 2.05 (1.71, 2.47)* 1.92 (1.60, 2.30)* 1.92 (1.42, 2.61)* 1.74 (1.42, 2.14)*
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prospective studies should further corroborate these find-
ings and explore underlying mechanisms.
A major finding in our study was that LOS was dou-
bled for both men and women with secondary CDI as
compared to those without. Moreover, at least 75% and
55% increases in total charges were noted among pneumo-
nia and UTI patients with CDI, respectively. In-hospital
mortality was also substantially higher among patients in
secondary CDI as compared to those without. Our findings
on the negative impact of CDI on patient and hospital
outcomes are in line with results noted among other
patient populations with CDI, such as inflammatory bowel
disease, solid organ transplant, and end stage renal failure
[11-14]; reflecting the substantial burden of CDI in vulner-
able patients.
We identified a number of hospital and patient charac-
teristics associated with CDI in patients with primary
pneumonia or UTI. Consistent with our results, previous
studies have reported a greater risk of CDI with increas-
ing age [29,38]. A study assessing C. difficile colitis case
fatality rate also noted higher rates among those in
Medicare and Medicaid [30], demonstrating the negative
burden of CDI among patients with such insurance
status, similar to trends noticed in our findings. We
hypothesize that given that Medicare patients are elderly,
they may be at a greater risk of negative outcomes and thus
the result noted in our study. In addition, Medicaid has
traditionally been for low income populations, and thus
limited resources, budget constraints, restrictions, etc.
could contribute to the negative rates. Not surprisingly
Table 3 Regression analyses of in-hospital mortality and health resource utilization upon secondary CDI among patients with pneu-
monia or urinary tract infectiona
In-hospital mortality Health resource utilization
OR (95% CI) Length of stay Total charge
IRR (95% CI) % change (95% CI)
Unadjusted Adjustedb Unadjusted Adjustedb Unadjusted Adjustedb
Primary pneumonia with secondary CDIc
Women 3.42 2.84 2.40 2.29 86.14 74.9
(3.03, 3.86)* (2.51, 3.21)* (2.30, 2.50)* (2.19, 2.39)* (80.36, 91.92)* (70.66, 79.20)*
Men 3.70 3.15 2.54 2.40 93.65 80.00
(3.28, 4.17)* (2.79, 3.55)* (2.43, 2.66)* (2.30, 2.52)* (87.93, 99.38)* (75.56, 84.48)*
Primary UTI with secondary CDId
Women 3.69 3.39 2.19 2.11 62.93 56.92
(2.82, 4.84)* (2.58, 4.44)* (2.06, 2.32)* (1.99, 2.24)* (57.08, 68.78)* (52.41, 61.44)*
Men 4.05 4.13 2.14 2.13 67.37 59.34
(2.89, 5.67)* (2.95, 5.78)* (1.99, 2.29)* (1.99, 2.29)* (59.23, 75.50)* (52.30, 66.38)*
*Bonferroni adjusted P < 0.0017
CDI = Clostridium difficile infection, UTI = Urinary tract infection, OR = odds ratio, CI = confidence interval, IRR = incidence rate ratio
aBinary logistic regression for in-hospital mortality, negative binomial regression for length of stay, linear regression for total charges. All procedures were
survey weighted
bModel adjusted for patient characteristics, hospital characteristics, and year
cReference = primary pneumonia no secondary CDI
dReference = UTI no secondary CDI
Table 2 Determinants of CDI among pneumonia and UTI discharges, NIS 2009-2011 (Continued)
Region
Northeast (ref.)
Midwest 0.94 (0.79, 1.11) 0.87 (0.73, 1.04) 0.99 (0.79, 1.23) 1.04 (0.86, 1.25)
South 0.79 (0.68, 0.91) 0.78 (0.66, 0.92) 0.82 (0.66, 1.01) 0.81 (0.68, 0.96)
West 0.83 (0.70, 0.97) 0.82 (0.69, 0.98) 0.78 (0.61, 1.01) 0.87 (0.72, 1.05)
Year
2009 (ref.)
2010 1.10 (0.97, 1.24) 0.96 (0.85, 1.08) 1.11 (0.93, 1.32) 1.03 (0.90, 1.19)
2011 1.06 (0.94, 1.20) 0.95 (0.84, 1.06) 1.06 (0.89, 1.26) 1.01 (0.88, 1.16)
CDI = Clostridium difficile infection, UTI = Urinary tract infection
*Bonferroni adjusted P < 0.0017
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and in keeping with other studies, we found that in-
creasing number of comorbidities, as reflected by the
Charlson Deyo index, was associated with a greater risk
for CDI [30].
We also reported higher odds of secondary CDI among
urban hospitals. Possible reasons include greater complexity
of illness or higher antibiotic prescribing practices among
urban hospitals [39], though some researchers have il-
lustrated the opposite [40] or non-significant differences
between urban or rural settings [41]. Future studies to
examine this issue with additional ways to account for
case mix are needed. Our findings of worse outcomes in
this large swath of hospitalized patients suggest opportun-
ities for both infection prevention and stewardship in this
population.
Our findings have major implications for clinicians and
healthcare institutions and add to the body of literature on
the prevalence and impact of CDI. The substantial nega-
tive impact of secondary CDI on in-hospital mortality and
health resource utilization emphasizes that those hospital-
ized for pneumonia or UTI represent high-risk patient
populations for CDI and should be included in CDI pre-
ventive efforts. Opportunities for optimizing antimicrobial
therapy use among patients to reduce such burden exists,
such as severity-based treatment, de-escalation as appro-
priate, and adherence to treatment guidelines for choice
and duration of anti-infectives [42,43]. Future studies to
examine interventions for reducing the risk of and mitigat-
ing the consequences of CDI in patients with pneumonia
and UTI are urgently needed.
Our results should be interpreted in the context of study
limitations. Given that NIS does not provide patient iden-
tifiable information, such ICD-9-CM codes could not be
cross-validated with laboratory results. Previous research,
however, has shown the validity and use of such codes for
CDI detection [44,45]. Second, the unit of observation in
NIS is discharges and not individual patients; therefore re-
sults of this study cannot assess the impact of initial versus
recurrent CDI. Third, while patient level characteristics,
such as age, gender, race/ethnicity, payer type, and neigh-
borhood income based on zip codes are included in the
NIS dataset, other social or medical determinants, such as
health literacy, education, dietary factors and treatments,
including outpatient procedures, could not be evaluated.
Conclusion
In our study, using the largest inpatient data in the
United States, we demonstrated that men have a signifi-
cantly higher prevalence of CDI, as compared to women.
CDI was also associated with increased in-hospital mor-
tality for both pneumonia and UTI patients, as well as
increased LOS and total charges; further highlighting the
negative impact of CDI and imperative need for prevent-
ive measures.
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